VIE News and Press, Viela Bio Inc. From 11/23/20

Viela Bio is an AstraZeneca-MedImmune spinoff. It has one approved drug and a long tailed pipeline. Their next catalyst is three to four years away. For further details see: Viela Bio: Startup With A Head Start

The following slide deck was published by Viela Bio, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Viela Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. Viela Bio Inc (NASDAQ: VIE) Q3 2020 Earnings Call Nov 10, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Viela Bio Inc (VIE) Q3 2020 Earnings Call Transcript

Viela Bio, Inc. (VIE) Q3 2020 Earnings Conference Call November 10, 2020, 05:00 PM ET Company Participants Mitchell Chan - CFO Bing Yao - Chairman and CEO Jörn Drappa - Chief Medical Officer and Head R&D Bill Ragatz - SVP, Head Commercial Conference Call Participants Seamus Fernandez...

VIELA BIO (VIE): Q3 GAAP EPS of -$0.69 beats by $0.08.Revenue of $2.32M misses by $1.36M.Viela had $387.5M in cash, equivalents, and investments and no outstanding debt.Press Release For further details see: VIELA BIO EPS beats by $0.08, misses on revenue

GAITHERSBURG, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today reported financial results and provided program ...

-- VIB7734 potently depleted blood and tissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases -- -- Treatment with VIB7734 resulted in clinically significant reduction in CLASI-A , ...

GAITHERSBURG, Md., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced it will host a webcast and conference ...

The following slide deck was published by Viela Bio, Inc. in conjunction with this Read more ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...